期刊文献+

醋酸艾塞那肽在大鼠体内的代谢分布(英文)

Tissue distribution of exendin-4 in rats
下载PDF
导出
摘要 目的研究醋酸艾塞那肽(exendin-4)在大鼠体内的组织分布。方法Iodo-GenTM法制备[125I]exendin-4,大鼠皮下注射[125I]exendin-4后,分别测定血浆或组织中的总放射性含量和酸沉淀放射性含量。结果[125I]exendin-4的酸沉淀放射性分布从高到低的顺序为肾脏>肺>膀胱>胰腺>肠>血浆>肾上腺>空肠>淋巴结>肝>脾>心脏>骨髓>胸腺>睾丸>脑>肌肉>脂肪。结论[125I]ex-endin-4的分布快速而广泛,其中以肾脏中最高,而在脑组织只发现微量的[125I]exendin-4。 AIM To investigate the tissue distribution of exendin-4 after administration in healthy rats. METHODS Exendin-4 was radioiodinated by the Iodo-Gen^TM method. Tissue distribution of [ ^125I]exendin-4 was inves- tigated after sc administration of [^125I ] exendin-4 at 3μg.kg.-1 in rats. Both total radioactivity and trichloroacetic acid (TCA) precipitated radioactivity were used to calculate the levels of [^125I ] exendin-4 in rats plasma and tissue samples after sc administration. RESULTS The tissue distribution of [ ^125I ] exendin-4 after sc injection showed substantial disposition in kidneys, lungs, bladder and pancreas. The rank order of normalized tissue distribution was kidneys 〉 lungs 〉 bladder 〉 pancreas 〉 intestine 〉 plasma 〉 adrenals 〉 jejunum 〉 lymph 〉 liver 〉 spleen 〉 heart 〉 marrow 〉 thymus 〉 testicles 〉 brain 〉 muscle 〉adipose. CONCLUSION [^125I]Exendin-4 un- derwent a rapid and wide distribution in the tissues throughout the whole body within the time course examined. TCA precipitated radioactivity in kidneys was the highest, however, only trace amounts of [ ^125I ] exendin-4 was detected in the brain.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2008年第2期95-101,共7页 Chinese Journal of Pharmacology and Toxicology
基金 国家高技术研究发展计划资助项目(2003AA2Z347B)~~
关键词 醋酸艾塞那肽 组织分布 药代动力学 exendin-4 tissue distribution pharmacokinetics
  • 相关文献

参考文献14

  • 1Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin3 analogue from Heloderma suspectum venom[J]. J Biol Chem, 1992, 267( 11 ) :7402 -7405.
  • 2Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-( 9-39 )-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting 13-cells[J]. J Biol Chem, 1993, 268 (26) : 19650 - 19655.
  • 3Edwards CMB, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and post-prandial glucose and decreases energy intake in healthy volunteers[ J]. Am J Physiol, 2001, 281 ( 1 ) : E155 - E161.
  • 4Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide ( synthetic exendin-4 ) : a potential therapeutic for improved glycemic control of type 2 diabetes [ J ]. Regul Pept, 2004, 117(2) : 77 -88.
  • 5Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes[J]. Eur J Pharm Sci, 2006, 28( 1 -2): 96 - 108.
  • 6Musch A, Heinzl S. Exenatide: an incretin mimetic for treatment of diabetes mellitus type 2 [ J ]. Med Monatsschr Pharm, 2006, 29 ( 3 ) : 86 - 89.
  • 7Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidylpeptidase Ⅳ resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity [ J]. Diabetologia, 1998, 41(3) :271 -278.
  • 8Federico C, Kristin T, Jenny H, Evelyn Z, Eh MC, Mattew W, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide ( synthetic exendin-4 ) [ J ]. Clin Ther, 2005, 27(2):210-215.
  • 9Koherman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus [ J ]. Am J Health Syst Pharm, 2005, 62(2) :173 - 181.
  • 10Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin- 4 in the rat: comparison with glucagon-like peptide-1 [J]. Drug Dev Res, 2001, 53(2) :260 -267.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部